Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 15/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232237 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2CASP1FOLH1 | |
| SCHEMBL6808253 | 0.86 | CASP1 (0.52) | SMN1; SMN2CASP1 | |
| SCHEMBL21332465 | 0.86 | CASP1 (0.47) | SMN1; SMN2CASP1FOLH1ALDH1A1 | |
| SCHEMBL10882993 | 0.86 | CASP1 (0.47) | SMN1; SMN2CASP1FOLH1ALDH1A1 | |
| SCHEMBL10884349 | 0.86 | CASP1 (0.47) | SMN1; SMN2CASP1FOLH1ALDH1A1 | |
| SCHEMBL3773280 | 0.84 | CTSK (0.48) | FOLH1 | |
| SCHEMBL863895 | 0.84 | CTSK (0.48) | FOLH1 | |
| SCHEMBL863894 | 0.84 | CTSK (0.48) | FOLH1 | |
| SCHEMBL15083134 | 0.84 | KMT2A (0.37) | SMN1; SMN2FOLH1 | |
| SCHEMBL25749303 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1371646-B1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2010-05-19 | — | — | EP | disclosed |
| US-7176199-B2 | Aryl-substituted alicyclic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1371646-A1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | ITGB3, ITGB1, ITGAL | SMN1; SMN2 3827/4885CASP1 2322/4885FOLH1 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.